Cargando…

Cefoperazone/sulbactam-induced hemolytic anemia

Drug-induced hemolytic anemia (DIHA) is a rare complication of drug therapy and usually underdiagnosed. Cefoperazone/sulbactam is a compound prepared from the third generation of cephalosporin and β-lactamase inhibitor. There are limited data of DIHA induced from cefoperazone/sulbactam. A 93-year-ol...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, XM, Liu, LH, Wu, Q, Wang, HG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997602/
https://www.ncbi.nlm.nih.gov/pubmed/34528516
http://dx.doi.org/10.4103/jpgm.JPGM_1335_20
_version_ 1784903289560629248
author Sun, XM
Liu, LH
Wu, Q
Wang, HG
author_facet Sun, XM
Liu, LH
Wu, Q
Wang, HG
author_sort Sun, XM
collection PubMed
description Drug-induced hemolytic anemia (DIHA) is a rare complication of drug therapy and usually underdiagnosed. Cefoperazone/sulbactam is a compound prepared from the third generation of cephalosporin and β-lactamase inhibitor. There are limited data of DIHA induced from cefoperazone/sulbactam. A 93-year-old female patient, who had an operation on the biliary tract 3 months ago, was admitted to our hospital with an abdominal infection. After cefoperazone/sulbactam was given as anti-infection treatment, the patient developed hemolytic anemia on the third day. Cefoperazone/sulbactam was discontinued and replaced with meropenem. Subsequently the level of red blood cells, hemoglobin, and hematocrit returned to normal. Clinicians should pay attention to monitoring the possible adverse reactions during the use of cefoperazone/sulbactam and should be aware of the occurrence of DIHA, so as to give timely treatment.
format Online
Article
Text
id pubmed-9997602
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-99976022023-03-10 Cefoperazone/sulbactam-induced hemolytic anemia Sun, XM Liu, LH Wu, Q Wang, HG J Postgrad Med ADR Report Drug-induced hemolytic anemia (DIHA) is a rare complication of drug therapy and usually underdiagnosed. Cefoperazone/sulbactam is a compound prepared from the third generation of cephalosporin and β-lactamase inhibitor. There are limited data of DIHA induced from cefoperazone/sulbactam. A 93-year-old female patient, who had an operation on the biliary tract 3 months ago, was admitted to our hospital with an abdominal infection. After cefoperazone/sulbactam was given as anti-infection treatment, the patient developed hemolytic anemia on the third day. Cefoperazone/sulbactam was discontinued and replaced with meropenem. Subsequently the level of red blood cells, hemoglobin, and hematocrit returned to normal. Clinicians should pay attention to monitoring the possible adverse reactions during the use of cefoperazone/sulbactam and should be aware of the occurrence of DIHA, so as to give timely treatment. Wolters Kluwer - Medknow 2023 2021-09-13 /pmc/articles/PMC9997602/ /pubmed/34528516 http://dx.doi.org/10.4103/jpgm.JPGM_1335_20 Text en Copyright: © 2021 Journal of Postgraduate Medicine https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle ADR Report
Sun, XM
Liu, LH
Wu, Q
Wang, HG
Cefoperazone/sulbactam-induced hemolytic anemia
title Cefoperazone/sulbactam-induced hemolytic anemia
title_full Cefoperazone/sulbactam-induced hemolytic anemia
title_fullStr Cefoperazone/sulbactam-induced hemolytic anemia
title_full_unstemmed Cefoperazone/sulbactam-induced hemolytic anemia
title_short Cefoperazone/sulbactam-induced hemolytic anemia
title_sort cefoperazone/sulbactam-induced hemolytic anemia
topic ADR Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997602/
https://www.ncbi.nlm.nih.gov/pubmed/34528516
http://dx.doi.org/10.4103/jpgm.JPGM_1335_20
work_keys_str_mv AT sunxm cefoperazonesulbactaminducedhemolyticanemia
AT liulh cefoperazonesulbactaminducedhemolyticanemia
AT wuq cefoperazonesulbactaminducedhemolyticanemia
AT wanghg cefoperazonesulbactaminducedhemolyticanemia